(2S,5S)-2-(Hydroxymethyl)-5-methylpyrrolidine | 152231-16-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2S,5S)-2-(Hydroxymethyl)-5-methylpyrrolidine
• 英文别名: (2S,5S)-2-hydroxymethyl-5-methylpyrrolidine；[(2S,5S)-5-methylpyrrolidin-2-yl]methanol
• CAS: 152231-16-8
• 化学式: C₆H₁₃NO
• 分子量: 115.175
• InChiKey: JMGBOXZFLWUSLH-WDSKDSINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (3E)-(2R,5S)-1-(Benzyloxy)-5-(p-toluenesulfonamido)-3-hexen-2-ol 在 platinum(IV) oxide 、 palladium on activated charcoal disodium hydrogenphosphate 、 sodium amalgam 、 trimethoxythioether 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 50.0 ℃ 、101.33 kPa 条件下， 反应 23.33h， 生成 (2S,5S)-2-(Hydroxymethyl)-5-methylpyrrolidine
  参考文献：
  名称：

  An enantioselective route to cis- and trans-2-(hydroxymethyl)-5-alkylpyrrolidines

  摘要：

  A general method for the enantioselective preparation of 2,5-disubstituted pyrrolidines has been developed. A variety of cis- and trans-2-(hydroxymethyl)-5-alkylpyrrolidin were synthesized using 1-(benzyloxy)-5-(p-toluenesulfonamido)-3-alken-2-ol as common intermediates.

  DOI：

  10.1021/jo00124a021

文献信息

• ANTIVIRAL THERAPEUTIC AGENTS
  申请人：Babu Yarlagadda S.

  公开号：US20090227524A1

  公开（公告）日：2009-09-10

  The invention provides compounds of Formula I: as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of Formula (I) are useful as anti-viral agents and/or as anti-cancer agents.

  该发明提供了如下的化合物I的公式，以及包含这些化合物的药物组合物，以及用于制备这些化合物的有用的合成方法和中间体。公式（I）的化合物可用作抗病毒剂和/或抗癌剂。
• [EN] BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS CYCLIQUES PONTÉS COMME INHIBITEURS DU VIRUS DE L'HÉPATITE C, COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS CORRESPONDANTES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015110048A1

  公开（公告）日：2015-07-30

  Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or harmaceutical com ositions thereof in the treatment of HCV infection or he atitis C.

  本文提供的是一种化合物，其化学式为（I）或其立体异构体、互变异构体、N-氧化物、水合物、溶剂合物、代谢产物、药学上可接受的盐或其前药，可用于治疗丙型肝炎病毒（HCV）感染或丙型肝炎疾病。此外，本文还提供了含有这些化合物的药物组合物以及使用这些化合物或药物组合物治疗HCV感染或丙型肝炎的方法。
• [EN] N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ D'AMINE N-ACYLE CYCLIQUE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2011111875A1

  公开（公告）日：2011-09-15

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1 and Ar2 are aryl or heteroaryl; V is nitrogen, or CR3; W1 is a single bond, -C(O)-, etc.; W2 is C1- alkylene; W3 is a single bond, methylene, -NH-, -CR4=CR5-, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R1a, R1b and R1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了一种化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍具有高效性，同时减少了传统的副作用风险，并对与精神分裂症以外的认知功能障碍相关的中枢神经系统疾病具有显著效果。提供了式（1）的N-酰基环胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4=CR5-等；环Q是式（a）的一组，其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a、R1b和R1c分别是相同或不同的氢、羟基、卤素、氰基、C1-6烷基等；或其药用可接受盐。
• NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS
  申请人：Pfizer Inc.

  公开号：US20140155390A1

  公开（公告）日：2014-06-05

  The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR 0 —, where R 0 is hydrogen, C 1 -C 6 linear or branched chain alkyl, etc., Z is —CR e —, or, —N—, where R e is hydrogen, C 1 -C 6 linear or branched chain alkyl,etc.; R 1 is hydrogen, C 1 -C 6 linear or branched chain alkyl, etc.; R 2 are independently hydrogen or C 1 -C 6 linear or branched chain alkyl; R 3 and R 4 are independently hydrogen, C 1 -C 6 linear or branched chain alkyl, etc.;. R 5 and R 6 are independently hydrogen or C 1 -C 6 linear or branched chain alkyl, etc.; R 8 is hydrogen, C 1 -C 6 linear or branched chain alkyl, etc.; R 9 and R 10 are independently hydrogen or C 1 -C 6 linear or branched chain alkyl, etc.; Q is —CO—, —(CH 2 ) q —, —(CHR s ) q —, or (CR s R t ) q —, where R s and R t are independently C 1 -C 6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.

  本发明涉及一种具有化学式1、2或3的化合物：其中A为N或—CR0—，其中R0为氢、C1-C6直链或支链烷基等，Z为—CRe—或—N—，其中Re为氢、C1-C6直链或支链烷基等；R1为氢、C1-C6直链或支链烷基等；R2独立地为氢或C1-C6直链或支链烷基；R3和R4独立地为氢、C1-C6直链或支链烷基等；R5和R6独立地为氢或C1-C6直链或支链烷基等；R8为氢、C1-C6直链或支链烷基等；R9和R10独立地为氢或C1-C6直链或支链烷基等；Q为—CO—、—(CH2)q—、—(CHRs)q—或(CRsRt)q—，其中Rs和Rt独立地为C1-C6直链或支链烷基、芳基、烷基芳基、杂芳基或烷基杂芳基；其中q为0、1、2或3；n为0、1、2、3、4或5；或其药学上可接受的盐，以及含有这种化合物的组合物；以及这种化合物在治疗各种疾病中的用途，特别是那些受雄激素受体影响或介导的疾病。
• New Diastereoselective Route to 2-Substitutedcis-(2S,5S)- andtrans-(2S,5R)-5-Alkylpyrrolidines as Indolizidine and Pyrrolizidine Scaffolds
  作者：Antonio J. Mota、Angèle Chiaroni、Nicole Langlois

  DOI：10.1002/ejoc.200300393

  日期：2003.11

  A new and short stereoselective route to the synthesis of enantiopure cis-2,5-disubstituted pyrrolidines as indolizidine or pyrrolizidine scaffolds has been developed. The method, which uses (S)-pyroglutamic acid as a chiral starting material, is based on the ring opening of N-protected γ-lactams by alkyl phenyl sulfone carbanions, followed by desulfonylation and reductive amination of alkyl γ-amino

  已经开发了合成对映体纯 cis-2,5-二取代吡咯烷作为吲哚里西啶或吡咯里西啶支架的新的短立体选择性路线。该方法使用 (S)-焦谷氨酸作为手性原料，基于烷基苯砜碳负离子对 N-保护的 γ-内酰胺开环，然后对烷基 γ-氨基酮进行脱磺酰化和还原胺化。非对映选择性取决于起始 γ-内酰胺的取代基和苯砜的烷基。在 5-烷基脯氨酸叔丁酯的形成过程中观察到总顺式非对映选择性。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)